Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has provided an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. said its business operations and clinical development activities remain normal despite recent unusual share price fluctuations, and the board is not aware of any undisclosed information that would explain the stock movements. The company also announced that China’s National Medical Products Administration has approved its investigational new drug application for IMM0306S, a subcutaneous formulation derived from its CD47/CD20 dual-targeting bispecific IMM0306, for systemic lupus erythematosus, reinforcing its position in advanced immune therapy development while retaining global intellectual property and commercial rights to the candidate.
The IND approval for IMM0306S allows ImmuneOnco to advance a novel subcutaneous therapy targeting the “don’t eat me” CD47-SIRPα pathway and CD20 on B cells in systemic lupus erythematosus. While the company cautioned there is no guarantee the drug will be successfully developed or commercialized, the regulatory green light marks a significant pipeline milestone that could broaden its clinical footprint in autoimmune diseases and signal long-term value potential for stakeholders if subsequent trials are successful.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a China-based biopharmaceutical company focused on developing innovative immuno-oncology and immune-related therapies. Its pipeline includes bispecific molecules such as IMM0306, which targets CD47 and CD20 to enhance immune-mediated elimination of malignant B cells while aiming to minimize toxicity, with a market focus on serious autoimmune and hematologic diseases.
Average Trading Volume: 1,333,108
Technical Sentiment Signal: Hold
Current Market Cap: HK$3.09B
For a thorough assessment of 1541 stock, go to TipRanks’ Stock Analysis page.